Adult BMT Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Supportive Care Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Palliat Med. 2020 Dec;23(12):1653-1657. doi: 10.1089/jpm.2019.0611. Epub 2020 Mar 27.
The myriad of benefits of early palliative care (PC) integration in oncology are well established, and emerging evidence suggests that PC improves symptom burden, mood, and quality of life for hematopoietic cell transplant (HCT) recipients. Specific impact of PC consultation on outcomes of older allogeneic HCT (allo-HCT) recipients, a historically high-risk population vulnerable to transplant-related complications and mortality, has not been explored. In this single institution, retrospective analysis of 527 first allo-HCT recipients aged ≥60 years, we characterized 75 patients who had received post-HCT PC consultation and its association with geriatric vulnerabilities identified by pre-HCT geriatric assessment. We also examined end-of-life care outcomes among patients who died within one-year of allo-hematopoietic cell transplantation. In multivariate analysis, higher disease risk, female gender, and, importantly, pre-HCT functional limitation (hazard ratio 2.35, 95% confidence interval, 1.35-4.09, = 0.003) were associated with post-HCT PC utilization. Within one-year of hematopoietic cell transplantation, 127 patients died; among those, recipients of early PC consultation had significantly higher rates of hospice enrollment (25% vs. 9%, = 0.019) and lower rates of hospital death (71% vs. 90%, = 0.013), intensive care unit admission (44% vs. 75%, = 0.001), and high-intensity medical care in last 30 days of life (46% vs. 77%, = 0.001). Our results highlight important pre-HCT risk factors associated with increased PC needs posthematopoietic cell transplantation and benefits of PC involvement for older allo-HCT recipients at the end of life. Prospective studies should examine the optimal timing of PC consultation and its multidimensional benefits for older allo-HCT patients.
早期姑息治疗(PC)在肿瘤学中的诸多益处已得到充分证实,新出现的证据表明 PC 可改善造血细胞移植(HCT)受者的症状负担、情绪和生活质量。PC 咨询对老年异基因 HCT(allo-HCT)受者结局的具体影响,allo-HCT 受者是一个历史上高危人群,易发生移植相关并发症和死亡,尚未得到探索。在这项单中心、回顾性分析中,我们对 527 名年龄≥60 岁的首次 allo-HCT 受者进行了分析,描述了 75 名接受 post-HCT PC 咨询的患者及其与 pre-HCT 老年评估确定的老年脆弱性的关系。我们还检查了 allo-hematopoietic 细胞移植后一年内死亡患者的临终关怀结局。在多变量分析中,更高的疾病风险、女性性别,以及重要的是,pre-HCT 功能障碍(危险比 2.35,95%置信区间 1.35-4.09,=0.003)与 post-HCT PC 的使用相关。在造血细胞移植后一年内,有 127 名患者死亡;在这些患者中,早期 PC 咨询的受者接受临终关怀的比例显著更高(25%比 9%,=0.019),住院死亡的比例更低(71%比 90%,=0.013),入住重症监护病房的比例更低(44%比 75%,=0.001),以及生命最后 30 天接受高强度医疗护理的比例更低(46%比 77%,=0.001)。我们的结果突出了与 posthematopoietic 细胞移植后 PC 需求增加相关的重要 pre-HCT 风险因素,以及 PC 对老年 allo-HCT 受者临终关怀的益处。前瞻性研究应检查 PC 咨询的最佳时机及其对老年 allo-HCT 患者的多维益处。